AEIdeas

The public policy blog of the American Enterprise Institute

Subscribe to the blog

Discussion: (6 comments)

  1. Martin Hutchinson

    And the reason for this is perfectly clear; the explosion of cheap leverage since 1995. Established companies can borrow more easily, and hence take advantage of this to wipe out their embryonic rivals.

  2. Citizen Buddy

    Three thougths:

    1) The huge outflow of jobs to countries that the U.S. does not have a Free Trade agreement with.

    2) High U.S. corporate tax keeping profits overseas and not used in the U.S.

    3) Government competition for funds, jobs and benefits.

  3. Todd Mason

    is it is possible that that the same corporate America that funds AEI also funds K Street and stacks the deck very effectively against rivals?

    http://blogs.law.stanford.edu/lawandbiosciences/2013/05/05/purdue-pharma-oxycontin-regulatory-gamesmanship-a-debate/

    (Purdue Pharma, as Oxycondin nears its patent end, introduces a formulation meant to prevent abuse.)

    1. juandos

      Is it possible that parasitic bureaucrats in government have driven the cost of doing business so high its not worth the effort to invest in what was quickly becoming a socialist hell hole?

      1. Todd Mason

        Is it possible that without stock options tempting CEOs to get rich quick, Big Pharma would not have been fined $13 billion for flogging off-label prescriptions to docs (i.e. demonstrating a nonparasitic purpose for regulators)?
        For example, Johnson & Johnson “targeted elderly dementia patients in nursing homes, and paid kickbacks to physicians and to the nation’s largest long-term care pharmacy provider, Omnicare Inc.”

        http://projects.propublica.org/graphics/bigpharma

  4. Joe Bannister

    Fascinating. And yet per capita incomes rising nicely through this time. Who cares?

Comments are closed.

Sort By:

Refine Content:

Scholar

Additional Keywords:

Refine Results

or to save searches.

Open
Refine Content